{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:27:30Z","timestamp":1766557650662},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"vor","delay-in-days":5181,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obesity Research"],"published-print":{"date-parts":[[1998,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold><jats:italic>Objective<\/jats:italic><\/jats:bold>: To assess weight loss, as well as the prevalence of valvular heart disease, in 21 obese women who completed 2 years of treatment by fenfluramine and phentermine (fen\u2010phen) in June 1997.<\/jats:p><jats:p><jats:bold><jats:italic>Research Methods and Procedures<\/jats:italic><\/jats:bold>: Patients were 21 of 22 women who had completed a 1\u2010year, <jats:italic>open\u2010label trial<\/jats:italic> of fen\u2010phen combined with lifestyle modification. This study describes the results of a second year of treatment. The presence of valvular heart disease, defined as aortic regurgitation of mild or greater severity and\/or mitral regurgitation of moderate or greater severity, was assessed using two\u2010dimensional, color Doppler and pulsed\u2010 and continuouswave Doppler examinations.<\/jats:p><jats:p><jats:bold><jats:italic>Results<\/jats:italic><\/jats:bold>: At 2 years, the 21 patients had a mean reduction in initial weight of 13.9 \u00b110.1%, which was significantly (<jats:italic>p<\/jats:italic>&lt;&lt;0.001) smaller than their 1\u2010year loss of 17.1 \u00b18.7%. Nine of 21 patients reported that they took fen\u2010phen irregularly during the last 4 months of the study because of fears of developing health complications. These nine patients had a 2\u2010year weight loss of 8.7 \u00b1 7.5%, compared with a significantly (<jats:italic>p<\/jats:italic>&lt;0.04) larger loss of 17.6 \u00b1 10.5% for participants who reported taking medication regularly. Six of 20 (30%) patients met criteria for valvular heart disease. None of the six had signs or symptoms of this condition.<\/jats:p><jats:p><jats:bold><jats:italic>Discussion<\/jats:italic><\/jats:bold>: Fenfluramine was withdrawn from the market on September 15, 1997 because of concerns that it was associated with valvular heart disease. The present findings are discussed in terms of the potentially favorable long\u2010term benefits of combining lifestyle modification with weight loss medications that are both safe and effective.<\/jats:p>","DOI":"10.1002\/j.1550-8528.1998.tb00350.x","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T18:27:48Z","timestamp":1346956068000},"page":"278-284","source":"Crossref","is-referenced-by-count":34,"title":["The Fen\u2010Phen Finale: A Study of Weight Loss and Valvular Heart Disease"],"prefix":"10.1002","volume":"6","author":[{"given":"Thomas A.","family":"Wadden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert I.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Silvestry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee A.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G. St. John","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Stunkard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary D.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Aber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"U.S. Department of Health and Human Services HHS News.FDA Announces Withdrawal of Fenfluramine and Dexfenfluramine. Rockville MD:1997."},{"key":"e_1_2_1_3_2","unstructured":"Wyeth\u2010Ayerst Laboratories.Pondimin and Redux to Be Voluntarily Withdrawn (letter to health care providers). Philadelphia PA:1997."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_1_5_2","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations, November 1997","volume":"46","author":"Bowen R.","year":"1997","journal-title":"MMWR."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801013380109"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1997.tb00296.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00016"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcn\/60.5.647","article-title":"Long\u2010term weight loss: the effects of pharmacologic agents","volume":"60","author":"Goldstein D.","year":"1994","journal-title":"Am J Clin Nutr."},{"key":"e_1_2_1_10_2","first-page":"24s","article-title":"A one year trial of orlistat in the management of obesity","volume":"21","author":"James WPT","year":"1997","journal-title":"lnt J Obes."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1996.tb00544.x"},{"key":"e_1_2_1_12_2","first-page":"30s","article-title":"Sibutramine\u2010a review of clinical efficacy","volume":"21","author":"Lean MEJ.","year":"1997","journal-title":"lnt J Obes."},{"key":"e_1_2_1_13_2","volume-title":"The LEARN Program for Weight Control","author":"Brownell KD.","year":"1994"},{"key":"e_1_2_1_14_2","volume-title":"The Weight Maintenance Survival Guide","author":"Brownell KD","year":"1990"},{"key":"e_1_2_1_15_2","volume-title":"Manual for the Beck Depression Inventory","author":"Beck AT","year":"1987"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/ajcn\/55.4.811","article-title":"A controlled comparison of three very\u2010low\u2010calorie diets: effects on weight, body composition, and symptoms","volume":"53","author":"Foster GD","year":"1992","journal-title":"Am J Clin Nutr."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(85)80477-0"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.70.4.657"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetitesuppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim L.","year":"1996","journal-title":"N Engl J Med."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00218.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.71"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00012"},{"key":"e_1_2_1_23_2","volume-title":"The Management of Eating Disorders","author":"Wadden TA"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.4.529"},{"key":"e_1_2_1_25_2","unstructured":"Knoll Pharmaceutical Company.MERIDIA (sibutramine hydrochloride monohydrate). Prescribing information provided in thePhysician's Desk Reference. Mount Olive NJ:1997."},{"key":"e_1_2_1_26_2","first-page":"219","article-title":"Sensitivity of the appetite control system in obese subjects to nutritional and serotonergic challenges","volume":"14","author":"Hill A J","year":"1990","journal-title":"lnt J Obes."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1998.tb00308.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00466.x"},{"key":"e_1_2_1_29_2","first-page":"397","article-title":"Beneficial effects of modest weight losses","volume":"16","author":"Goldstein D.","year":"1992","journal-title":"lnt J Obes."},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ajcn\/56.1.44","article-title":"Lipid and insulin concentrations in obese postmenopausal women: separate effects of energy restriction and weight loss","volume":"56","author":"Weinsier RL","year":"1992","journal-title":"Am J Clin Nutr."},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ajcn\/62.2.350","article-title":"Weight loss and changes in serum lipids and lipoproteins in obese women","volume":"62","author":"Andersen RE","year":"1995","journal-title":"Am J Clin Nutr."},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90302-6"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400070100012"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","article-title":"Long\u2010term pharmacotherapy in the management of obesity","volume":"276","author":"National Task Force on the Prevention and Treatment of Obesity.","year":"1996","journal-title":"JAMA."}],"container-title":["Obesity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1550-8528.1998.tb00350.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1550-8528.1998.tb00350.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:15:13Z","timestamp":1700759713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/j.1550-8528.1998.tb00350.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["10.1002\/j.1550-8528.1998.tb00350.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1550-8528.1998.tb00350.x","archive":["Portico"],"relation":{},"ISSN":["1071-7323","1550-8528"],"issn-type":[{"value":"1071-7323","type":"print"},{"value":"1550-8528","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}